Loading company…
QRL Bioscience develops cell-based therapies for chronic non-healing wounds.
Based in Gujarat, India, QRL Bioscience develops therapies for chronic wounds, including QRLBIO001, an autologous live cell-based treatment for diabetic foot and venous leg ulcers. Its proprietary Autologous Advanced Biologics platform uses cells to support wound healing. In August 2025, the company raised INR 30 million from GVFL to advance clinical trials for its diabetic foot ulcer therapy and preclinical development of an osteoarthritis treatment.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in